Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2007, Pages

  Volmink, Jimmy ^a   Siegfried, N L ^b   Van Der Merwe, L ^b   Brocklehurst, P ^b  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b NONE

Author keywords

Anti HIV agents *therapeutic use ; Disease transmission, vertical *prevention control ; HIV infections prevention control; *transmission ; Nevirapine therapeutic use

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; PLACEBO; STAVUDINE; ZIDOVUDINE;

ABNORMAL LABORATORY RESULT; ANEMIA; ASPHYXIA; ASPIRATION PNEUMONIA; BLOOD TOXICITY; CLINICAL TRIAL; COCHRANE LIBRARY; DATA BASE; DIARRHEA; DYSPNEA; EMBASE; HEMATOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; INFECTION PREVENTION; INFECTION RISK; LIVER TOXICITY; LOADING DRUG DOSE; MALNUTRITION; NEUTROPENIA; OUTCOMES RESEARCH; PNEUMONIA; RASH; RESPIRATORY DISTRESS SYNDROME; RESPIRATORY TRACT DISEASE; REVIEW; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; VIRUS TRANSMISSION;

EID: 41849117498     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003510.pub2     Document Type: Review

References (108)

1. Bhoopat 2005 {published data only} *Bhoopat L, Khunamornpong S, Lerdsrimongkol P, Sirivatanapa P, Sethavanich S, Limtrakul A, et al.Effectiveness of short-term and long-term zidovudine prophylaxis on detection of HIV-1 subtype E in human placenta and vertical transmission. Journal of Acquired Immune Deficiency Syndromes 2005;40:545-50.
2. DITRAME {published data only} Dabis F, Elenga N, Meda N, Leroy V, Viho I, Manigart O, Dequae-Merchadou L, et al.18-Month mortality and perinatal exposure to zidovudine in West Africa. AIDS 2001;15:2204-5.
3. Dabis F, Msellati P, Meda N, Leroy V, Van De Perre P, Merchadou L, et al.Infant mortality and perinatal exposure to zidovudine in Africa. XIII International AIDS Conference, Durban 2000;Abstract MoPpB1024.
4. *Dabis F, Msellati P, Meda N, Welffens-Ekra C, You B, Manigart O, et al.6-month efficacy, tolerance and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. Lancet 1999;353:786-92.
5. Dabis F, Msellati P, Newell ML, Halsey N, Van de Perre P, Peckham C, et al.Methodology of intervention trials to reduce mother to child transmission of HIV with special reference to developing countries. International Working Group on Mother to Child Transmission of HIV. AIDS 1995;9:Suppl A:S67-74.
6. DITRAME ANRS 049 Study Group. 15-month efficacy of maternal oral zidovudine to decrease vertical transmission of HIV-1 in breastfed African children. Lancet 1999;354:2050-1.
7. Msellati P, Ramon R, Viho I, et al.Prevention of mother-to-child transmission of HIV in Africa: uptake of pregnant women in a clinical trial in Abidjan, Cote d'Ivoire. AIDS 1998;12:1257-8.
8. Gray 2005 {published data only} Gray GE, Urban M, Chersich MF, Bolton C, van Niekerk R, Violari A, et al.A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers. AIDS 2005;19:1289-97.
9. Gray 2006 {published data only} *Gray G, Violari A, McIntyre J, Jivkov B, Schnittman S, Reynolds L, et al.Antiviral activity of nucleoside analogues during short-course monotherapy or dual therapy: Its role in preventing HIV infection in infants. Journal of Acquired Immune Deficiency Syndromes 2006;42.
10. Gray 2006 a {published data only} *See Gray 2006.
11. Gray 2006 b {published data only} See Gray 2006.
12. Gray 2006 c {published data only} See Gray 2006.
13. HIVNET 012 {published data only} Eshleman SH, Guay LA, Mwatha A, Brown E, Musoke P, Mmiro F, et al.Comparison of mother-to-child transmission rates in Ugandan women with subtype A versus D HIV-1 who received single-dose nevirapine prophylaxis: HIV Network For Prevention Trials 012. Journal of Acquired Immune Deficiency Syndromes 2005;39:593-7.
14. Eshleman SH, Guay LA, Wang J, Mwatha A, Brown ER, Musoke P, et al.Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012. Journal of Acquired Immune Deficiency Syndromes 2005;40:24-9.
15. Eshleman SH, Hoover DR, Chen S, Hudelson SE, Guay LA, Mwatha A, et al.Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. The Journal of Infectious Diseases 2005;192:30-6.
16. Flys T, Nissley DV, Claasen CW, Jones D, Shi C, Guay LA, et al.Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. The Journal of Infectious Diseases 2005;192:1-3.
17. *Guay L, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al.Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354:795-802.
18. Jackson JB, Musoke P, Fleming T, Guay LA, Bagenda D, Allen M, et al.Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003;362:859-68.
19. James JS. IOM: nevirapine study is reliable. AIDS Treatment News 2005 March 25:411.
20. Owor M, Desyve M, Duefield C, et al.The one year safety and efficacy data of HIVNET 012 trial. XIII International AIDS Conference, Durban. 2000; Vol. LbOr1.
21. Kiarie 2003 {published data only} *Kiarie JN, Kreiss JK, Richardson BA, John-Stewart GC. Compliance with antiretroviral regimens to prevent perinatal HIV-1 transmission in Kenya. AIDS 2003;17:65-71.
22. Limpongsanurak 2001 {published data only} Limpongsanurak S, Thaithumyanon P, Chaithongwongwatthana S, Thisyakorn U, Ruxrungtham K, Kongsin P, et al.Short course zidovudine maternal treatment in HIV-1 vertical transmission: randomized controlled multicenter trial. Journal of the Medical Association of Thailand 2001;84:Suppl 1:S338-45.
23. PACTG 076 {published data only} Connor E, Mofenson L. Zidovudine for the reduction of perinatal human immunodeficiency virus transmission: Pediatric AIDS Clinical Trials Group Protocol 076 - results and treatment recommendations. The Pediatric Infectious Disease Journal 1995;14:536-41.
24. *Connor E, Sperling R, Gelber R, Kiselev P, Scott G, O'Sullivan M, et al.Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. The New England Journal of Medicine 1994;331:1173-80.
25. Sperling R, Shapiro D, Coombs R, Todd J, Herman S, McSherry G, et al.Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. The New England Journal of Medicine 1996;335:1621-9.
26. Sperling R, Shapiro D, McSherry G, Britto P, Cunningham B, Culnane M, et al.Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 study. AIDS 1998;12:1805-1813.
27. PACTG 316 {published data only} *Dorenbaum A. Report of results of PACTG 316: An international phase III trial of standard antiretroviral (ARV) prophylaxis plus nevirapine (NVP) for prevention of perinatal HIV transmission. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, February 2001. 2001.
28. Dorenbaum A, Cunningham CK, Gelber RD, Culnane M, Mofenson L, Britto P, et al.Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. The Journal of the American Medical Association 2002;288:189-98.
29. PETRA {published data only} *PETRA study team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet 2002;359:1178-86.
30. PETRA a {published data only} See PETRA.
31. PETRA b {published data only} See PETRA.
32. PETRA c {published data only} See PETRA.
33. PHPT-1 {published data only} *Lallemant M, Jourdain G, Le Couer S, Kim S, Koetsawang S, Comeau A, et al.A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. NEJM 2000;343:982-991.
34. PHPT-1 a {published data only} *See PHPT-1.
35. PHPT-1 b {published data only} See PHPT-1.
36. PHPT-2 {published data only} Cressey TR, Jourdain G, Lallemant MJ, Kunkeaw S, Jackson JB, Musoke P, et al.Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. Journal of Acquired Immune Deficiency Syndromes 2005;38:283-8.
37. *Lallemant M, Jourdain G, Le Coeur S, Mary JY, Ngo-Giang-Huong N, Koetsawang S, Kanshana S, et al.Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. The New England Journal of Medicine 2004;351:217-28.
38. RETRO-CI {published data only} Sibailly T, Ekpini E, Boni-Ouattara E, Nkengasong J, Maurice C, Kouassi M, et al.Clinical course of HIV infection and surveillance for zidovudine resistance among HIV-infected women receiving short-course zidovudine therapy in Abidjan, Cote d'Ivoire. XIII International AIDS Conference, Durban. 2000; Vol. Abstract TuPeC3354.
39. *Wiktor S, Ekpini E, Karon J, Nkengasong J, Maurice C, Severin S, et al.Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial. Lancet 1999;353:781-5.
40. SAINT {published data only} Moodley D, Moodley J, Coovadia H, Gray G, McIntyre J, Hofmyer J, et al.Amulticenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. The Journal of Infectious Diseases 2003;187:725-35.
41. Taha 2003 {published data only} Eshleman SH, Hoover DR, Hudelson SE, Chen S, Fiscus SA, Piwowar-Manning E, et al.Development of nevirapine resistance in infants is reduced by use of infant-only single-dose nevirapine plus zidovudine postexposure prophylaxis for the prevention of mother-to-child transmission of HIV-1. The Journal of Infectious Diseases 2006;193:479-81.
42. Taha TE, Kumwenda N, Kafulafula G, Kumwenda J, Chitale R, Nkhoma C, et al.Haematological changes in African children who received short-term prophylaxis with nevirapine and zidovudine at birth. Annals of Tropical Paediatrics 2004;24:301-9.
43. Taha TE, Kumwenda NI, Gibbons A, Broadhead RL. Fiscus S, Lema V, et al.Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial. Lancet 2003;362:1171-77.
44. Taha 2004 {published data only} Eshleman SH, Hoover DR, Hudelson SE, Chen S, Fiscus SA, Piwowar-Manning, et al.Development of nevirapine resistance in infants is reduced by use of infant-only single-dose nevirapine plus zidovudine postexposure prophylaxis for the prevention of mother-to-child transmission of HIV-1. The Journal of Infectious Diseases 2006;193:479-81.
45. Taha TE, Kumwenda N, Kafulafula G, Kumwenda J, Chitale R, Nkhoma C, et al.Haematological changes in African children who received short-term prophylaxis with nevirapine and zidovudine at birth. Annals of Tropical Paediatrics 2004;24:301-9.
46. Taha TE, Kumwenda NI, Hoover DR, Fiscus SA, Kafulafula G, Nkhoma C, et al.Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial. The Journal of the American Medical Association 2004;292:202-9.
47. Thai-CDC {published data only} Bhadrakom C, Simonds R, Mei J, Asavapiriyanont S, Sangtaweesin V, Vanprapar N, et al.Oral zidovudine during labour to prevent perinatal HIV transmission, Bangkok: tolerance and zidovudine concentration in cord blood. AIDS 2000;14:509-516.
48. Chotpitaysaunondh T, Vanprapar N, Simonds R, Chokephaibulkit K, Waranawat N, Mock P, et al.Safety of late in utero exposure to zidovudine in infants born to human immunodeficiency virus-infected mothers: Bangkok. Pediatrics 2001;107:E5.
49. Roongpisuthipong A, Siriwasin W, Asavapiriyanont S, Chaisilwattana P, Schaffer N, Mock P, et al.Predictors of mortality in 18-month postpartum period among HIV-infected women enrolled in a trial of short-course antenatal zidovudine, Bangkok, Thailand. XIII International AIDS Conferecce, Durban. 2000; Vol. Abstract TuPeB3253.
50. *Shaffer N, Chuachoowong R, Mock P, Bhadrakom C, Siriwasin W, Young NL, et al.Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet 1999;353:773-80.
51. Vuthipongse P, Bhadrakom C, Chasisiiwattana P, Roongpisuthipong A, Chalermchokcharoenkit A, Chearskul S, et al.Administration of zidovudine during late pregnancy and delivery to prevent perinatal HIV transmission - Thailand 1996-1998. MMWR 1998;47(8):151-4.
52. Thistle 2004 {published data only} Thistle P, Gottesman M, Pilon R, Glazier RH, Arbess G, Phillips E, et al.A randomized control trial of an Ultra-Short zidovudine regimen in the prevention of perinatal HIV transmission in rural Zimbabwe. The Central African Journal of Medicine 2004;50:79-84.
53. El Beitune 2005 El Beitune P, Duarte G, Machado AA, Quintana SM, Figueiro-Filho EA, Abduch R. Effect of antiretroviral drugs on maternal CD4 lymphocyte counts, HIV-1 RNA levels, and anthropometric parameters of their neonates. Clinics 2005;60:207-12.
54. Leroy 2002 Leroy V, Karon JM, Alioum A, Ekpini ER, Meda N, Greenberg AE, et al.Twenty-four month efficacy of a maternal short-course zidovudine regimen to prevent mother-to-child transmission of HIV-1 in West Africa. AIDS 2002;16:631-41.
55. Leroy 2005 *Leroy V, Sakarovitch C, Cortina-Borja M, McIntyre J, Coovadia H, Dabis F, et al.Is there a difference in the efficacy of peripartum antiretroviral regimens in reducing mother-to-child transmission of HIV in Africa?. AIDS 2005;19:1865-75.
56. Shetty 2003 *Shetty AK, Coovadia HM, Mirochnick MM, Maldonado Y, Mofenson LM, Eshleman SH, Fleming T, Emel L, George K, Katzenstein DA, Wells J, Maponga CC, Mwatha A, Jones SA, Abdool Karim SS, Bassett MT, HIVNET 023 Study Team. Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. J Acquir Immune Defic Syndr 2003;34:482-90.
57. Yoshimoto 2005 Yoshimoto CE, Diniz EM, Vaz FA. Clinical and laboratory evolution of children born to HIV positive mothers [Evolução clínica e laboratorial de recém-nascidos de mães HIV positivas]. Revista da Associação Médica Brasileira 2005;51:100-5.
58. BAN 2005 Bentley ME, Corneli AL, Piwoz E, Moses A, Nkhoma J, Tohill BC, et al.Perceptions of the role of maternal nutrition in HIV-positive breast-feeding women in Malawi. The Journal of Nutrition 2005;135:945-9.
59. SIMBA Ongoing study Starting date of trial not provided. Contact author for more information.
60. Alioum 2003 Alioum A, Cortina-Borja M, Dabis F, Dequa-Merchadou L, Haverkamp G, Highes J, et al.Estimating the efficacy of interventions to prevent mother-to-child transmission of human immunodeficiency virus in breast-feeding populations: comparing statistical methods. American Journal of Epidemiology 2003;158:596-605.
61. Altman 2005 RG Newcombe, DG Altman. Proportions and their differences. In: DGAltman, DMachin, TNBryant, MJGardner editor(s). Statistics with confidence. 2nd Edition. Bristol: MBJ Books, 2005.
62. Birkhead 2000 Birkhead G, Wade N, Storfer-Isser A, Gallagher B, Singh T, Bornschlegel K. Review of deaths among a cohort of New York State (NYS) infants exposed in the perinatal period to HIV and antiretroviral drugs [Abstract 692]. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, USA. 2000.
63. Blanche 1999a Blanche S, Rouzioux C, Mandelbrot L, Delfraissy J, Mayaux M. Zidovudine-lamivudine for prevention of mother to child HIV-1 transmission. Sixth Conference on Retroviruses and Opportunistic Infections [Abstract 267]. Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, USA. 1999.
64. Blanche 1999b Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtion G, Ciraru-Vigneron N, Lacroix C, Rouzioux C, Mandelbrot L, Desguerre I, Rotig A, Mayaux M-J, Delfraissy. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999;354:1084-89.
65. Bulterys 2000 Bulterys M, Nesheim S, Abrams EJ, Palumbo P, Farley J, Lampe M, et al.Lack of evidence of mitochondrial dysfunction in the offspring of HIV-infected women. Retrospective review of perinatal exposure to antiretroviral drugs in the Perinatal AIDS Collaborative Transmission Study. Annals of the New York Academy of Sciences 2000;918:212-21.
66. Chaix 2005 Chaix M, Dabis F, Ekouevi D, Rouet F, Tonwe-Gold B, Viho I, et al.Addition of 3 days of ZDV+3TC postpartum to a short course of ZDV+3TC and single-dose NVP provides low rate of NVP resistance mutations and high efficacy in preventing peri-partum HIV-1 transmission: ANRS DITRAME Plus, Abidijan, Cote d'Ivoire [oral LB72]. The 12th Conference on Retroviruses and Opportunistic Infections, San Francisco, USA. 2005.
67. Connor 1994 Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al.Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. New England Journal of Medicine 1994;331:1173-80.
68. Culnane 1999 Culnane M, Fowler M, Lee SS, McSherry G, Brady M, O'Donnell K, et al.Lack of long-term effects of in utero exposure to zidovudine among uninfected childen born to HIV-infected women. JAMA 1991;281:151-7.
69. Dabis 1995 Dabis F, Msellati P, Newell ML, Halsey N, Van de Perre P, Peckham C, et al.Methodology of intervention trials to reducemother-to-child transmission of HIV with special reference to developing countries. AIDS 1995;9 Suppl A:S67-S74.
70. Dunn 1992 Dunn D, Newell M-L, Ades A, Peckham C. Risk of human immunodeficiency virus type 1 transmission through breast-feeding. Lancet 1992;240:585-8.
71. Dunn 1994 Dunn DT, Newell ML, Mayaux MJ, Kind C, Hutto C, Goedert JJ, et al.Mode of delivery and vertical transmission of HIV-1: a review of prospective studies. Journal of Acquired Immune Deficiency Syndromes 1994;7:1064-6.
72. Eshleman 2001 Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick M, Musoke P, Fleming T, Glenn Fowler M, Mofenson LM, Mmiro F, Jackson JB. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET012). AIDS 2001;15(15):1951-7.
73. Eshleman 2005a Eshleman S, Nissley D, Claasen C, Jones D, Shi C, Guay L, et al.Sensitive drug resistance assays reveal long-term persistence of HIV-1 variants with the K103N nNevirapine-resistance mutation in some women and infants after single-dose NVP: HIV-NET 012 [poster 800]. The 12th Conference on Retroviruses and Opportunistic Infections, San Francisco, USA. 2005.
74. Eshleman 2005b Eshleman SH, Hoover DR, Chen S, Hudelson SE, Guay LA, Mwatha A, et al.Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. Journal of Infectious Diseases 2005;192:30-6.
75. European Collab 1992 European Collaborative Study. Risk factors for mother-to-child transmission of HIV-1. European Collaborative Study. Lancet 1992;339:1007-12.
76. Ghent 2001 The Ghent Group: Alioum A, Dabis F, Dequae-Merchadou L, Haverkamp G, Hudgens M, Hughes J, Karon J, Leroy V, Newell ML, Richardson B, Weverling GJ. Estimating the efficacy of interventions to prevent mother-to-child transmission of HIV in breastfeeding populations: development of consensus methodology. Statistics in Medicine 2001;20:3539-56.
77. Giuliano 2005 Giuliano M, Galluzzo C, Germinario E, Amici R, Pirillo M, Bassani L, et al.Selection of resistance mutations in children receiving prophylaxis with lamivudine or nevirapine for the prevention of postnatal transmission of HIV [oral 99]. The 12th Conference on Retroviruses and Opportunistic Infections, San Francisco, USA. 2005.
78. Hammer 1997 Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al.A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less.New England Journal of Medicine 1997;337:725-33.
79. Hammer 2005 Hammer SM. Single-dose nevirapine and drug resistance: the more you look, the more you find. Journal of Infectious Diseases 2005;192:1-3.
80. Hanson 2000 Hanson C, Frederick M, McIntosh K. Evaluation of living uninfected children for mitochondrial defects: Women and Infants Transmission Study. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco. 2000; Vol. Abstract 665.
81. Hill 1999 AM Hill. A meta-analysis of the effects of HIV-1 RNA methodology on estimates of HIV-1 RNA undetectability in trials of HAART. Conf Retrovirus Opportunistic Infect. 1999; Vol. 6.
82. HIV Group 1999 The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1. New England Journal of Medicine 1999;340:977-87.
83. Jamieson 2003 Jamieson DJ, Sibailly TS, Sadek R, Roels TH, Ekpini ER, Boni-Ouattara E, et al.HIV-1 viral load and other risk factors for mother-to-child transmission of HIV-1 in a breast-feeding population in Cote d'Ivoire. Journal of Acquired Immune Deficiency Syndromes 2003;34:430-6.
84. John 1996 John GC, Kreiss J. Mother-to-child transmission of human immunodeficiency virus type 1. Epidemiologic Reviews 1996;18:149-57.
85. Johnson 2005 Johnson JA, Li JF, Morris L, Martinson N, Gray G, McIntyre J, et al.Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. Journal of Infectious Diseases 2005;192:16-23.
86. Jourdain 2004 Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanuwong C, Kantipong P, Leechanachai P. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. New England Journal of Medicine 2004;351:229-40.
87. Khouri 1995 Khouri YF, McIntosh K, Cavacini L, Posner M, Pagano M, Tuomala R, et al.Vertical Transmission of HIV-1. Correlation with maternal viral load and plasma levels of CD4 binding site anti-gp120 antibodies. Journal of Clinical Investigation 1995;95:732-7.
88. Landesman 1996 Landesman SH, Kalish LA, Burns DN, Minkoff H, Fox HE, Zorilla C, et al.Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. New England Journal of Medicine 1996;334:1617-23.
89. Mandelbrot, 2001 Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, Berrebi A, Benifla JL, Burgard M, Lachassine E, Barret B, Chaix ML, Bongain A, Ciraru-Vigneron N, Crenn-Hebert C, Delfraissy JF, Rouzioux C, Mayaux MJ, Blanche S, Agence Nationale de Recherches sur le SIDA (ANRS) 075 Study Group. Lamivudine-zidovudine combination for prevention of maternal infant transmission of HIV-1. JAMA 2001;285(16):2083-93.
90. Marseille 1999 Marseille E, Kahn J, Mmiro F, Guay L, Musoke P, Fowler M-G, et al.Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. Lancet 1999;354:803-809.
91. McIntyre 2005 McIntyre J. Controversies in the use of nevirapine for the prevention of mother-to-child transmission [Plenary 7]. The 12th Conference on Retroviruses and Opportunistic Infections, San Francisco, USA. 2005.
92. Minkoff 1995 Minkoff H, Burns DN, Landesman S, Youchah J, Goedert JJ, Nugent RP, et al.The relationship of the duration of ruptured membranes to vertical transmission of human immunodeficiency virus. American Journal of Obstetrics and Gynecology 1995;173:585-9.
93. Miotti 1999 Miotti PG, Taha TE, Kumwenda NI, Broadhead R, Mtimavalye LA, Van der Hoeven L, et al.HIV transmission through breastfeeding: a study in Malawi. JAMA 1999;282:744-9.
94. Mirochnick 1998 Mirochnick M, Fenton T, Gagnier P, Pav J, Gwynne M, Siminski S, et al.Pharmacokinetics of nevirapine in human immunodeficiency virus type-1 infected pregnant women and their neonates. Journal of Infectious Diseases 1998;178:368-74.
95. Mofenson 1994 Mofenson LM. Epidemiology and determinants of vertical HIV transmission. Seminars in Pediatric Infectious Diseases 1994;5:252-6.
96. Mofenson 1995 Mofenson LM. A critical review of studies evaluating the relationship of mode of delivery to perinatal transmission of human immunodeficiency virus. Pediatric Infectious Disease Journal 1995;14:169-76.
97. Morcroft 2000 Morcroft A, Katlama C, Johnson A, Pradier C, Antunes F, Mulcahy F, et al.AIDS across Europe, 1994-98: the EUROSIDA study. Lancet 2000;356:291-96.
98. Morris 2000 Morris A, Cu-Uvin S, Harwell J, Garb J, Zorrilla C, Vajaranant M, et al.Multicentre review of protease inhibitors in 89 pregnancies. Journal of Acquired Immune Deficiency Syndromes 2000;25:306-11.
99. Musoke 1999 Musoke P, Guay L, Bagenda D, Mirochnick M, Nakabiito C, Fleming T, et al.A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1 infected pregnant Ugandan woman and their neonates (HIVNET 006). AIDS 1999;13:479-86.
100. Nair 1993 Nair P, Alger L, Hines S, Seiden S, Hebel R, Johnson JP. Maternal and neonatal characteristics associated with HIV infection in infants of seropositive women. Journal of Acquired Immune Deficiency Syndromes 1993;6:298-302.
101. Palmer 2005 Palmer S, Boltz V, Maldarelli F, Martinson N, Gray G, McIntyre J, et al.Persistence of NNRTI-r resistant variants after single-dose nevirapine in HIV-1 subtype-C-infected women [poster 101]. The 12th Conference on Retroviruses and Opportunistic Infections, San Francisco, USA. 2005.
102. Semba 1994 Semba RD, Miotti PG, Chiphangwi JD, Saah AJ, Canner JK, Dallabetta GA, et al.Maternal vitamin A deficiency and mother-to-child transmission of HIV-1. Lancet 1994;343:1593-7.
103. Siegfried 2005 Siegfried N, Clarke M, Volmink J. Randomised controlled trials in Africa of HIV and AIDS: descriptive study and spatial distribution. BMJ 2005;331:742-7.
104. UNAIDS/WHO 2005 UNAIDS/WHO. AIDS epidemic update. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS) December 2005.
105. Wade 1998 Wade N, Birkhead G, Warren B, Charbonneau T, French P, Wang L, et al.Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. New England Journal of Medicine 1998;339:1409-14.
106. Walker 2002 Walker N, Schwartlander B, Bryce J. Meeting international goals in child survival and HIV/AIDS. Lancet 2002;360:284-9.
107. Working Group 1995 The Working Group on MTCT of HIV. Rates of mother-to-child transmission of HIV-1 in Africa, America and Europe: results of 13 perinatal studies. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1995;8:506-10.
108. Eshleman SH, Gu3 Eshleman SH, Guay LA, Mwatha A, Brown E, Musoke P, Mmiro F, et al.Comparison of mother-to-child transmission rates in Ugandan women with subtype A versus D HIV-1 who received single-dose nevirapine prophylaxis: HIV Network For Prevention Trials 012. Journal of Acquired Immune Deficiency Syndromes 2005;39:593-7.